Announcements - OBI Pharma

2026.Mar.09

The Company's Board of Directors resolved to convene the 2026 Annual General Shareholders' Meeting

2026.Mar.09

Announcement of the Company’s accumulated losses have reached one-half of paid-in capital

2026.Mar.09

Announcement of not Distributing Dividends in 2025

2026.Mar.09

Announcement of 2025 Consolidated Financial Statements were approved by the Board of Directors

2026.Feb.26

Announcement for the expected date of the Board of Directors Meeting for 2025 financial reports is 2026/03/09

2026.Feb.04

The Company received notice from SWOG regarding the analysis results of Phase II Stage 1 clinical trial of OBI-3424 in T-ALL and T-LBL

2025.Dec.31

Announcement of completion of the Company’s capital change registration and adjustment to the share replacement plan

2025.Dec.19

The Company’s BOD resolved to enter into commercial licensing agreement with TegMine for the development of glycoprotein monoclonal antibody ADC

2025.Dec.19

Announcement of BOD’s resolution to lift the non-competition restrictions for managerial officer

2025.Dec.19

Announcement pursuant to Article 22.1(3) of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies

News

Latest News

Events

Latest events